97 related articles for article (PubMed ID: 27276062)
1. CD24 Expression May Play a Role as a Predictive Indicator and a Modulator of Cisplatin Treatment Response in Head and Neck Squamous Cellular Carcinoma.
Modur V; Joshi P; Nie D; Robbins KT; Khan AU; Rao K
PLoS One; 2016; 11(6):e0156651. PubMed ID: 27276062
[TBL] [Abstract][Full Text] [Related]
2. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.
Jiffar T; Yilmaz T; Lee J; Hanna E; El-Naggar A; Yu D; Myers JN; Kupferman ME
Oncogene; 2011 Jul; 30(28):3163-73. PubMed ID: 21383688
[TBL] [Abstract][Full Text] [Related]
3. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
[TBL] [Abstract][Full Text] [Related]
4. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
[TBL] [Abstract][Full Text] [Related]
5. Grp78 as a therapeutic target for refractory head-neck cancer with CD24(-)CD44(+) stemness phenotype.
Chiu CC; Lee LY; Li YC; Chen YJ; Lu YC; Li YL; Wang HM; Chang JT; Cheng AJ
Cancer Gene Ther; 2013 Nov; 20(11):606-15. PubMed ID: 24201869
[TBL] [Abstract][Full Text] [Related]
6. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.
Yoo GH; Lin HS; Iskander AJ; Piechocki MP; Oliver J; Kewson D; Lonardo F; Tainsky MA; Kim HR; Kim H; Ensley JF
Laryngoscope; 2005 Nov; 115(11):1938-46. PubMed ID: 16319602
[TBL] [Abstract][Full Text] [Related]
8. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma.
Yamano Y; Uzawa K; Saito K; Nakashima D; Kasamatsu A; Koike H; Kouzu Y; Shinozuka K; Nakatani K; Negoro K; Fujita S; Tanzawa H
Int J Cancer; 2010 Jan; 126(2):437-49. PubMed ID: 19569180
[TBL] [Abstract][Full Text] [Related]
9. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
10. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
11. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
12. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.
Burkitt K; Ljungman M
Cancer Lett; 2007 Aug; 253(1):131-7. PubMed ID: 17321670
[TBL] [Abstract][Full Text] [Related]
13. Role of neurofilament light polypeptide in head and neck cancer chemoresistance.
Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z
Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235
[TBL] [Abstract][Full Text] [Related]
14. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines.
Lee SK; Kim SB; Kim JS; Moon CH; Han MS; Lee BJ; Chung DK; Min YJ; Park JH; Choi DH; Cho HR; Park SK; Park JW
Int J Cancer; 2005 Oct; 117(1):32-40. PubMed ID: 15880358
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-conjugating enzyme UBE2Q2 suppresses cell proliferation and is down-regulated in recurrent head and neck cancer.
Maeda H; Miyajima N; Kano S; Tsukiyama T; Okumura F; Fukuda S; Hatakeyama S
Mol Cancer Res; 2009 Sep; 7(9):1553-62. PubMed ID: 19723876
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.
Govindan SV; Kulsum S; Pandian RS; Das D; Seshadri M; Hicks W; Kuriakose MA; Suresh A
Mol Med Rep; 2015 Aug; 12(2):3025-32. PubMed ID: 25962396
[TBL] [Abstract][Full Text] [Related]
17. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic differences in cisplatin sensitivity of head and neck cancer cell lines: Correlation to lysosomal pH.
Nilsson C; Roberg K; Grafström RC; Ollinger K
Head Neck; 2010 Sep; 32(9):1185-94. PubMed ID: 20029982
[TBL] [Abstract][Full Text] [Related]
19. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
20. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
